‘Accelerate, accelerate, accelerate’ – a Pfizer executive explains how the integration of continuous manufacturing helped the company deliver drugs to patients faster.
After a low cost of manufacturing goal was achieved by a consortium for the development of a bioproduction system for vaccines, Univercells will launch its NevoLine system.
This week in-PharmaTechnologist attended AAPS PharmSci360 in Washington, D.C. where discussions and thought-provoking ideas bounced across sessions – here, we highlight some of the most significant.
Pfizer and GlaxoSmithKline have agreed to work together on the development of a new version of the former's continuous processing technology for oral solid dosage (OSD) drugs.
Despite pharma being “highly regulated and slow to change,” continuous manufacturing will soon be realised, says Rutgers University which has received an R&D grant from J&J.
Continuous processing is still hamstrung by a lack of control systems and is not ready for specific FDA guidance according to an industry expert panel which met at Interphex last week.
At this week's Informex show in New Orleans, experts at a packed
out session discussed the potential of up-and-coming continuous
processing technologies and posed the question: is batch processing
yesterday's technology?
